ストックスクリーナーアプリを入手
3.32
2.35%
-0.08
アフターアワーズ：
3.30
-0.02
-0.60%
Incannex Healthcare Inc (IXHL) 最新ニュース
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
Incannex Healthcare | 10-K: Annual report - Moomoo
Incannex Healthcare Inc. FY 2026: Revenue $0 Net income ($19.3M), EPS ($1.66) — 10-K Summary - TradingView
Incannex Healthcare Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Why Did Incannex (NASDAQ:IXHL) Dose Its First Sleep-Apnea Patient? - Kalkine Media
Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com South Africa
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Begins Dosing in Phase 2 Sleep Apnea Trial - minichart.com.sg
Incannex begins Phase 2 dosing study for sleep apnea drug - Investing.com
A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan
IXHLIncannex Healthcare Inc Revenue Breakdown - Finviz
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Enterprise value to EBIT forward of Incannex Healthcare Limited – LSX:A2DF4D - TradingView
IXHL Should I Buy - intellectia.ai
IXHL Q4'26 Earnings: EPS estimate is (0.14) USD - TradingView
Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29ETF Premium Discount - vinanet.vn
What’s Next for Incannex Healthcare (ASX:IHL) After US Patent Win? - Kalkine Media
IXHL Q4'26 Earnings: revenue estimate is 0 USD - TradingView
Incannex doses first patient in sleep apnea drug trial By Investing.com - Investing.com Nigeria
Incannex doses first patient in sleep apnea drug trial - Investing.com India
Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus
Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - Quiver Quantitative
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Barchart.com
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - Kalkine Media
Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media
Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media
Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusTrend Continuation Trade - vinanet.vn
Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn
Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan
Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media
Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media
Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media
Incannex Healthcare Inc. (IXHL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incannex Healthcare Inc. (IXHL) options chain - Yahoo Finance Singapore
Incannex Secures A$5.1M R&D Tax Incentive Refund - theglobeandmail.com
Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight? - Kalkine Media
Why Are BrainChip (ASX:BRN), Incannex Healthcare (ASX:IHL), Lake Resources (ASX:LKE) and Cann Group (ASX:CAN) Back in the Market Spotlight? - Kalkine Media
Incannex receives final A$5.1m R&D tax incentive refund By Investing.com - Investing.com UK
Incannex Healthcare Inc. (IXHL) stock price, news, quote and history - Yahoo Finance Singapore
Incannex receives final A$5.1m R&D tax incentive refund - Investing.com
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - The Manila Times
Form 8K Incannex Healthcare Inc. For: 11 August By Investing.com - Investing.com Nigeria
Press Release: Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 - Moomoo
Incannex receives A$5.1M final R&D refund, totaling A$11.2M non-dilutive funding - TradingView
IXHL Forecast & Price Target - TradingKey
Can Incannex (ASX:IHL) Reshape The Cannabis Conversation? - Kalkine Media
Incannex Healthcare Inc (IXHL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incannex Healthcare Inc. (IXHL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Incannex Healthcare Inc (IXHL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
0.18%
0.69%
大文字化:
|
ボリューム (24 時間):